A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Loss of tumor suppressor (TS) gene function drives cancer initiation and progression.
• Targeting oncogenes is successful, but restoring TS function remains difficult.
• E3 ubiquitin ligases accelerate TS protein degradation in cancer, making them viable therapeutic targets.

Purpose of the Study:

• To review E3 ligases that negatively regulate TS proteins.
• To explore the development status of E3 inhibitors.
• To assess the therapeutic potential and challenges of E3 inhibitors in precision medicine.

Main Methods:

• Literature review of E3 ligases targeting TS proteins.
• Analysis of current E3 inhibitor development, including MDM2 inhibitors.
• Evaluation of E3 inhibition as a therapeutic strategy for cancer.

Main Results:

• E3 ligase inhibitors offer greater selectivity than broad-spectrum proteasomal inhibitors.
• Enhancing TS protein expression via E3 inhibition is feasible for wild-type TS proteins.
• Advances in E3 inhibitor development show promise for specific cancer treatments.

Conclusions:

• E3 ligase inhibition represents a promising strategy for anti-cancer precision medicine.
• Targeting E3 ligases can restore TS protein function and combat cancer.
• Further research is needed to overcome pitfalls and optimize E3 inhibitors for therapeutic use.